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Background: Since extraintestinal sites of inflammation have been demonstrated in patients
with Crohn’s disease (CD) and ulcerative colitis (UC), both entities are regarded as systemic
disorders. There are only scarce data on the prevalence of inflammatory bowel disease
(IBD)-associated lung involvement in children.
Objectives: The aim of our study was to investigate pulmonary involvement in pediatric
patients with IBD.
Material and methods: Fifty children with IBD (25 UC and 25 CD, mean age 14.2  3.2 yrs) and
39 age-matched, healthy, control subjects were included in the study. Pulmonary function
testing, methacholine bronchial challenge, fractional exhaled nitric oxide (FeNO) and high
resolution computed tomography (HRCT) were used to detect functional and/or structural
pulmonary involvement.
Results: There were no differences in spirometric parameters, lung volumes or lung diffusion
capacity for carbon monoxide between IBD patients and control subjects. Highly significant
differences were found in FeNO between CD, UC and control patients (mean 9.3  3.3,
27.7  14.8 and 16.6  9.28, respectively; p Z 0.000). Bronchial hyperresponsiveness was
diagnosed in six IBD cases (14.6%). HRCT (performed in 32 patients from the study group) re-
vealed mild bilateral bronchiectasis in one patient.
Conclusions: The prevalence of pulmonary involvement in children with IBD is low. Screening
for pulmonary involvement in children and young adults with IBD may enable early detection of
IBD-related pulmonary diseases which, seems to be notably more common in adult patients.
Elevated FeNO could probably be regarded as a marker of airway involvement in non-
smoking UC pediatric patients. This requires further studies.
ª 2012 Elsevier Ltd. All rights reserved.24523265; fax: þ48 224523204.
ail.com (J. Peradzynska).
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BHR bronchial hyperresponsiveness
CD Crohn’s disease
DLCO diffusing lung capacity for carbon
monoxide
ERS European Respiratory Society
FeNO fractional exhaled nitric oxide
FEV1 forced expiratory volume in 1 s
FVC forced vital capacity
HRCT high resolution computed tomography
IBD inflammatory bowel disease
MEF25 maximal expiratory flow at 25% of vital
capacity
MEF50 maximal expiratory flow at 50% of vital
capacity
PCDAI Pediatric Crohn’s Disease Activity Index
PFT pulmonary function tests
PUCAI Pediatric Ulcerative Colitis Activity
Index
UC ulcerative colitis
RV residual volume
TLC total lung capacity
TGV thoracic gas volumeIntroduction
Nowadays, Crohn’s disease (CD) and ulcerative colitis (UC)
are regarded as systemic disorders. Extraintestinal sites of
inflammation have been found in various organs, including
the respiratory system.
The features of the inflammation involving the respira-
tory system include lymphocytic, mononuclear or poly-
morphonuclear cell infiltration, as well as granuloma
formation within the airway mucosa and in the lung
parenchyma. These pathologic changes can lead to clinical
manifestations such as bronchitis, bronchiolitis, interstitial
pneumonitis, or pleuritis.1,2 There are no precise data on
the prevalence of inflammatory bowel disease (IBD)-asso-
ciated lung involvement. The most common pulmonary
manifestations in patients with IBD include: cough, pleu-
ritic chest pain, sputum production and shortness of
breath.3 Some authors reported a relationship between
both IBD duration and severity and the prevalence of
pulmonary involvement.4,5
Data on CD related pulmonary disease in children are
scarce.6e10 They include mainly case reports and case
series. Only 2 studies evaluated the prevalence, type and
severity of pulmonary involvement in a prospective
manner.3,6 Surprisingly, we were not able to find any
publications on pulmonary manifestations in children with
UC. Diagnosis of pulmonary involvement in children with
IBD seems important because most of these conditions are
steroid-responsive.11 Thus, early diagnosis gives the
opportunity for effective treatment.
The aim of our study was to investigate pulmonary
involvement in pediatric patients with IBD. The specificgoals were as follows: 1) to compare the prevalence and
2) to compare the prevalence of lung parenchymal changes
and bronchial involvement, 3) to evaluate the relationship
between IBD duration and activity and the occurrence of
pulmonary changes, 4) to assess the usefulness of different
diagnostic methods in the evaluation of pulmonary abnor-
malities in children with IBD.
Material and methods
Study population
The study group consisted of 50 IBD patients (25 with UC
and 25 with CD, mean age 14.2  3.2 yrs) treated in the
Department of Pediatric Gastroenterology and Nutrition,
Medical University of Warsaw. Diagnosis of CD and UC was
established in accordance with the Porto criteria.12 Activity
of the CD and UC was evaluated using the Pediatric Crohn’s
Disease Activity Index (PCDAI) and the Pediatric Ulcerative
Colitis Activity Index (PUCAI). PCDAI score  10 for CD and
PUCAI score  10 for UC were defined as remission. IBD
duration was defined as time between the IBD diagnosis and
inclusion into this study. Recruitment to the study did not
affect treatment which had been continuously applied due
to gastrointestinal symptoms (Table 1).
The control group, consisting of 39 healthy children
(mean age 14.0  3.5 yrs), was recruited concurrently.
In both study groups pulmonary function testing was
applied to assess lung ventilation and gas exchange. BHR
and FeNO were used as indirect markers of airway inflam-
mation. Structural alterations in the lungs were evaluated
with high resolution computed tomography (HRCT).
Pulmonary function tests
All patients underwent spirometry with flow-volume curve
analysis (Spirometer Lungtest 1000, MES, Poland) as well as
whole body-pletysmography (Bodypletysmograph Lungtest
1000, MES, Poland). All the pulmonary function parameters
are presented as the number of standard deviations from
reference value (z-score). Airway obstruction was diag-
nosed if z-score for FEV1/FVC ratio was below e 2.
Abnormal small airways flow was diagnosed if MEF50 and
MEF25 z-score was below 2.13 Z-score for TLC lower than
e 2 was considered significant for a restrictive ventilatory
defect. Lung diffusing capacity for carbon monoxide (DLCO)
was measured by single-breath method using V-max 22
system (Sensor-Medics, USA). DLCO, adjusted to haemo-
globin concentration, values below 80% and above 120%
predicted were regarded as abnormal.
FeNO measurement
Fractional exhaled nitric oxide (FeNO) was measured with
a chemiluminescence nitric oxide analyzer (NIOA, Sievers,
USA) during single-breath exhalation and according to the
ATS/ERS (American Thoracic Society/European Respiratory
Society) guidelines.14 FeNO values are reported in parts per
billion (ppb). Concentrations higher than 35 ppb (for
Table 1 Characteristics of the study groups.
CD N Z 25 UC N Z 25 Controls N Z 39 P value
Mean age in years (SD) 14.3 (3.3) 14.1 (3.3) 14.0 (3.5) NS
Male/female 16/9 10/15 20/19 NS
Systemic steroid use 3 9 0
Other treatment
Mesalazine 24 8 Not applicable
Azatiopryne 18 9
Sulfasalazine 2 15
Weight in kg (SD) 53.4 (17.4) 50.0 (12.5) 52.8 (16.8) NS
Height in cm (SD) 155.4 (30.4) 159.8 (14.3) 161.5 (16.7) NS
Time from diagnosis in months (SD) 23.2 (20.68) 20.1 (19.4) Not applicable NS
Mean disease activity index (SD) PCDAI Index 7.4 (11.2) PUCAI Index 13 (15.7) Not applicable NS
Disease activity (number of patients) Remission 21 Remission 11
Mild 2 Mild 12 Not applicable
Moderate 2 Moderate 2
CD e Crohn’s disease, UC e ulcerative colitis, SD e standard deviation, NS e not significant, PCDAI e Pediatric Crohn’s Disease Activity
Index, PUCAI - Pediatric Ulcerative Colitis Activity Index.
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>12 years) was considered abnormal.15Bronchial hyperreponsiveness
Bronchial responsiveness was assessed by methacholine
challenge test using dosimetric method, according to the
ATS guidelines (Lungtest 1000, ISPA, MES, Poland). BHR was
diagnosed at 20% FEV1 fall compared to FEV1 measured
after dilutant (saline).16High resolution computed tomography
HRCT was performed with a 16-row CT scanner (LightSpeed
16 General Electric, USA). The following parameters were
applied: collimation - 1.0 mm, 1 s scanning time, current -
100 kV, 100 mA, matrix size 512 512. The CT image data
were reconstructed with a high spatial frequency algorithm
and viewed at a window level of e 450 HU and a window
width of 1500 HU. Images were acquired at full inspiration
and full expiration.Statistical analysis
Statistical analysis was performed with STATISTICA soft-
ware, version 9.0 (StatSoft, Tulsa, OK, USA). Variables
were expressed as mean and standard deviation. Differ-
ences between continuous variables in groups were
calculated with KruskaleWallis test. The Chi- squared test
was used to assess the proportions of patients with
abnormal results of different parameters in the study
groups. Correlation between various indices of pulmonary
involvement and diseases duration and activity was per-
formed with Spearman’s correlation test. All P values
were 2-tailed and P < 0.05 was considered statistically
significant.Ethical considerations
The study protocol was accepted by Ethics Committee of
Medical University of Warsaw (KB/96/2008) and a written
informed consent was obtained from both the participants
and their legal guardians.Results
Characteristics of patients from the study and control
groups is presented in Table 1. There were no smokers
either in the study or in the control group. Seven patients
from the study group (5 in CD and 2 in UC group) had
positive history of atopy (asthma e one patient, atopic
dermatitis eone patient, allergic rhinitis e five patients).
Six patients had complained of respiratory symptoms
(chronic or recurrent cough or dyspnea) before entering the
study. In all of these patients atopic diseases were diag-
nosed previously to the study onset.Pulmonary function testing
The prevalence of ventilatory lung function impairment in
IBD patients was low and not different from that found in
control group (Table 2). A restrictive ventilatory pattern
was demonstrated in only one patient (2%) (CD group).
Airway obstruction was showed in two IBD patients (4%) (CD
group) and in two patients (5.1%) from the control group.
Small airway tests were abnormal in 13 (26%) subjects from
the study group (8 and 5 in CD and UC group, respectively)
and in 13 (33%) control subjects.
DLCO was abnormal in 9 (18%) (5 in CD, 4 in UC group)
and 6 (15.3%) children from the study and the control
group, respectively. There was no significant difference in
the DLCO value between the study and control groups
(Table 2).
No correlation between disease activity and any of PFT
parameters or DLCO in study groups was found.
Figure 1 Fractional exhaled nitric oxide (FeNO) in Crohn’s
disease group (CD), ulcerative colitis group (UC), and controls.
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Mean FeNO was 9.3 ppb (SD 3.3), 27.7 ppb (SD 14.8) and
16.6 ppb (SD 9,28) in CD, UC and control group, respec-
tively. The differences in FeNO were highly significant
(p Z 0.000) and regarded all inter-group comparisons
(p Z 0.000)(Fig. 1). In 4 patients with UC, FeNO level
exceeded the upper limit of normal.
Forty one children from IBD group underwent meth-
acholine challenge test. Bronchial hyperresponsiveness was
diagnosed in six cases (14.6%): 1 in CD and 5 in UC group.
Two of these patients had positive history of atopy (allergic
rhinitis).
Imaging studies
HRCTwas performed in 32 patients from the study group. In
all but one child, HRCT showed a normal parenchymal
pattern. Mild bronchiectases in both upper lobes were
found in one, 15 year-old, girl. She was asymptomatic and
had no history of previous lung diseases.
Discussion
Our study showed that functional and structural pulmonary
involvement in children with IBD is quite uncommon. As the
study was based on the pre-defined, rigorous protocol and
involved the largest group of children with IBD reported in
the English literature, we believe, the presented results are
fully reliable. Another advantage of our study might be the
inclusion not only CD but also UC patients. To our knowl-
edge, there were no previous studies assessing pulmonary
involvement in children with UC.
Pulmonary function testing
The prevalence of ventilatory lung function impairment in
IBD patients was surprisingly low. Interestingly, all patients
with abnormal ventilatory pattern were found in the CD
subgroup.
The most common spirometric abnormality, demon-
strated in 26% of patients from the study group, was
a decrease in MEF50 and MEF25 values. However, low MEF50
and MEF25 were also demonstrated in 33% of the control
patients. These findings emphasize the importance ofTable 2 Pulmonary function parameters in study groups.
Parameter CD group mean (SD) UC g
FEV1 z-score 0.1 (1,0) 0.
FVC z-score 0.01 (0.9) 0.
FEV1/FVC z-score 0.2 (1.2) 0.
MEF50 z-score 0.6 (1.2) 0.
MEF25 z-score 1.1 (1.3) 0.9
TLC z-score 1.0 (1.3) 1.
DLCO % of predicted value 94.5 (19.96) 90.
CD e Crohn’s disease, UC e ulcerative colitis, FEV1 e forced expirator
expiratory flow at 50, 25 percent of vital capacity (respectively), TLC
monoxide.considering the results of measurements in a matched
control group when interpreting the study outcomes.
The second most common abnormal finding in PFT was
lung diffusion impairment as shown by decreased DLCO
values in 9 (18%) children with IBD. However, there was
neither a difference in DLCO value, nor in the proportion of
patients with abnormal DLCO between study and control
group. Thus, we believe it is not justifiable to conclude that
decreased DLCO is a valuable or a specific marker of lung
involvement in children with IBD.
There are several reasons making a comparison between
our results and the results of previous studies difficult.
First, only one prospective study evaluating PFT in 26
pediatric patients with CD has been published.6 However,
this study was focused on differences in PFT results in
patients with active vs. non-active disease. The authors
could not show any difference in lung volumes and expi-
ratory flows in these two groups.6 In our study, there was no
difference in PFT, measured in patients with active vs. non-
active disease, neither was there a correlation between
disease activity and any PFT parameter value. More in-
depth comparison of these two studies is limited by fact
that Munk et al. evaluated only CD patients and these
authors did not include control subjects in their study.6roup mean (SD) Control group mean (SD) P value
3 (0.97) 0.2 (0.98) NS
3 (0.9) 0.1 (0.9) NS
3 (0.9) 0.1 (0.96) NS
2 (1.2) 0.7 (1.2) NS
8 (1.2) 1.3 (1.1) NS
3 (1.7) 0.2 (2.2) NS
3 (18.0) 101.8 (22.00) NS
y volume in 1 s, FVC e forced vital capacity, MEF50, 25 e maximal
e total lung capacity, DLCO e diffusing lung capacity for carbon
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Nevertheless, on the basis of the report by Munk et al. and
our study, it might be concluded that in children with IBD
there is no relationship between disease activity and
ventilatory lung function.
Second, in our study the abnormal PFT results were
defined using z-score, which is the method recommended
by ERS, particularly in children.17 All previous publications,
except those where the definition of normal range was not
provided,18 presented PFT measurements as percentage of
normal value with abnormal results defined as those below
a certain, pre-defined percent of predicted.19 Of note, cut-
off values ranging from 70 to 89% were applied in different
studies. Particularly, a pre-defined cut-off percentage
value of the FEV1/FVC ratio (usually 70%), was used to
diagnose airway obstruction.20 This approach can be
misleading, and result in underdiagnosis of airway
obstruction. Hence, we believe our analysis may add to the
existing literature, especially that the results were
compared with well matched control group.
Although, the results of our study can be compared with
the results of some adult studies, it should be stressed,
that neither the prevalence, nor the pattern of pulmonary
involvement in adults with IBD do necessarily reflects those
observed in children. A comprehensive literature review
published in 2007 summarized adult studies which were
designed to compare PFT in IBD and control subjects.21
Most of the analyzed papers have consistently found
subtle or no spirometric abnormalities in IBD patients.21
Three publications demonstrated considerable hyperinfla-
tion defined as increased RV, FRC or RV/TLC ratio as
compared with control subjects.22e24 In one paper, the
prevalence of abnormal PFT results (FEV1 and FVC) was
significantly higher in IBD than in control subjects and
positively correlated with disease activity.25 In two other
studies, small airway obstruction was observed and the
authors found a significantly higher incidence of airflow
limitation in the subgroup of IBD patients with active
disease.26,27
Since 2007, several papers on pulmonary function in
adults with IBD have been published. Yilmaz et al. showed
that PFT were impaired in 22 of 39 patients with IBD (CD
and UC) and the most prevalent change was decreased FEF
25%e75% (43.58%). Moreover, 7.7% of patients had an
obstructive and 5.1% had a restrictive pattern of respiratory
dysfunction. The differences in PFT results between the
study and the control group were significant.18 In contrast
with these results, Ozyilmaz et al. found large airway
obstruction (FEV1/VC) only in 2 out of 33 patients with IBD
(CD and UC) and no difference in PFT between the study
and the control group.20
A number of studies have demonstrated a decreased
DLCO in adults with IBD as compared to control subjects
and it seems to be the most common abnormal finding in an
IBD patients.20,21,28 Moreover, a correlation between
disease activity and DLCO has been found in some
studies.6,27,28 In only one study in children significantly
lower DLCO in subjects with active as compared to non-
active CD patients were demonstrated.6 In our study,
however, there was no difference in DLCO, measured in
patients with active vs. non-active disease, neither was
there a correlation between disease activity and DLCOvalue. Thus, we believe, the pattern of DLCO changes in
children with active vs. non-active IBD requires further
studies.BHR and FeNO
The most prominent difference between CD, UC and
control patients in our study was FeNO concentration.
Differences in FeNO between CD and UC could reflect the
different pathogenesis of these two entities. Th2-
dependent inflammatory response is regarded as a typical
feature of UC. Specific Th2 cytokines and chemo-
attractants, e.g. IL-5, released in the inflammatory sites
are responsible for the increased eosinophil count and
activity and may lead to increased FeNO.29,30 This seems to
be confirmed in a study by Fireman et al.31 The authors
found an elevated eosinophil count in induced sputum from
patients with UC. Conversely to UC, Th1 inflammatory type
predominates in CD patients. Therefore, eosinophilic
inflammation is not seen in the affected organs. Fireman
et al. found an elevated CD4/CD8 ratio in induced sputum
from CD patients, while the eosinophil count was within the
normal range.32
The difference between FeNO in UC and CD patients
could be affected by steroid treatment.15 While as many as
36% of our UC patients received steroid treatment, as
compared to only 12% of CD patients, we may speculate
that if they had not been treated with steroids, FeNO in UC
patients would have even been higher and the difference
between UC and CD and control patients would have even
been more significant. Since no data on FeNO levels in
pediatric patients with IBD are available, our findings can
be only compared to adult studies. Koek et al. showed
a significant FeNO difference between CD, UC and control
patients with highest FeNO values in the UC group. More-
over, they found a positive correlation with disease
activity. These authors concluded, that increased FeNO in
active IBD and its correlation with disease activity, provide
evidence on the systemic nature of the IBD.33
Ozyilmaz et al. showed a difference in FeNO concen-
tration between adult IBD patients with and without
pulmonary involvement (mean values 32 and 24 ppb,
respectively). However, the mean values in both groups
were within normal limit.20 The authors concluded that
increased FeNO may be used for identifying patients with
IBD who need further pulmonary evaluation. However,
sensitivity and specificity analysis failed to determine cut-
off value of FeNO levels which could reliably distinguish
patients with and without pulmonary involvement.
Several studies in adults and one study in children
assessed bronchial responsiveness in patients with IBD.3
Mansi et al. reported BHR in as many as 10 from 14 chil-
dren with CD participating in that study. The BHR was not
related to CD duration or disease activity. The authors
suggested that such a high prevalence of BHR in their
patients could be explained by a higher prevalence of BHR
in children as compared to adults.3 In one adult study, Louis
et al. demonstrated a significantly higher prevalence of
BHR in IBD patients (45%) than in healthy controls (17%).34
The results of our study are different than those reported
by Mansi et al.3 In our study group BHR was diagnosed in
Low prevalence of pulmonary involvement in children with inflammatory bowel disease 1053only 6/41 (14.6%) of patients. Of note is the fact that Mansi
et al. as well as some other authors, presented the results
as provocating dose (PD).3,35 According to ATS guidelines we
used the provocative concentration (PC) that results in
a 20% fall in FEV1 (PC20) to measure bronchial responsive-
ness. This is because it is simple to calculate and avoids the
complicated and controversial aspects of estimating
a provocative dose (PD20).16
The positive methacholine challenge as an evidence of
pulmonary involvement in IBD should be interpreted with
caution because of high prevalence of positive results in
the general population. In a recently published study Liem
et al. found that diagnosis of BHR at the value of PC
20 < 8 mg/ml yields with 52% positive results in healthy
children.36HRCT
We found a very low prevalence of pulmonary HRCT
changes in children with IBD. Again, there are no data from
children studies which could be compared to our observa-
tion. In adult IBD patients the prevalence of radiologic
abnormalities was much higher. Mahadeva et al. revealed
different types of pulmonary involvement (mostly bron-
chiectases, air trapping and “tree in bud” changes) in 14 of
17 investigated patients.37 Spira et al. noted an abnormal
HRCT pattern in 5 of 7 investigated patients.38 In both
studies, however, the HRCT was performed in symptomatic
patients and this could probably explain the high preva-
lence of pulmonary changes. In a recent paper by Yilmaz
et al., HRCT abnormalities were found in as many as 25/39
(64,1%) of adults with CD and UC. The most common find-
ings were: peribronchial thickening, bronchiectases,
ground glass opacities and emphysema.18 In our study, the
very low prevalence of HRCT abnormalities correlated with
the absence or low incidence of abnormal PFTs and suggests
that pulmonary involvement in children with IBD is signifi-
cantly less common than in adults.Conclusions
Although some abnormalities in parameters characterizing
respiratory structure and function can be revealed in chil-
dren with IBD, their prevalence is not higher than that
found in healthy subjects. There are no evidences that
disease activity and its duration are correlated with any of
the lung function parameters. It seems that lung involve-
ment in children with IBD is less common than in adult
patients. Thus, we may hypothesize the first symptoms of
pulmonary function impairment probably appear in late
childhood, adulthood or in young adults. Screening for
pulmonary involvement in these patient groups might be an
important part of clinical assessment enabling an early
detection of pulmonary dysfunction. Elevated FeNO could
probably be regarded as a marker of airway involvement in
UC pediatric, non-smoking patients. This requires further
studies. Conversely to adult studies, decreased DLCO does
not seem to be a reliable marker of lung involvement in
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